Clopidogrel for the Prevention of Exacerbations in Severe COPD

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a debilitating respiratory disorder characterized by gradual and progressive airflow limitation. It has been hypothesized that clopidogrel may have a role in reducing the exacerbation of COPD by reducing thromboembolic events. Several observational studies have found that taking clopidogrel reduces the likelihood of COPD exacerbations in patients with the disease. The study being conducted will be a randomized control trial, from March 2023 to March 2024 in the department of pulmonology, LRH. The aim of the study is to determine the role of clopidogrel in reducing the frequency of exacerbation in COPD patients compared to controls. The sampling will be done by non-probability consecutive sampling and the patients will be randomly allocated in study and control groups. Both the groups will be followed at the 3rd, 6th, and 12th months of the treatment and will be compared for the outcomes.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lady Reading Hospital, Pakistan
• Collaborator: Pakistan Chest Society, Pakistan
• Treatments: Clopidogrel

Criteria

Inclusion Criteria:

• Patients diagnosed with severe COPD (GOLD stage III or IV based on FEV1)

• Patients with a history of at least one exacerbation in the past year.

• Patients who are able to understand and provide informed consent.

• Patients willing and able to comply with the study protocol and attend follow-up visits.

• Patients who are between the ages of 40 and 80 years.

• Either gender

Exclusion Criteria:

• Patients who have previously experienced serious medical issues, like a recent heart attack or stroke (within six months),

• Patients who are known to be hypersensitive to clopidogrel.

• People who have a history of gastrointestinal bleeding or any other health issue that could make them more likely to bleed.

• Women who are pregnant or nursing.

• Patients who are being treated with additional antiplatelet or anticoagulant medications.

• Patients who are being treated with clopidogrel for any other indication.

• People who suffer from severe renal or liver illness.